SCHEMBL6018680

SCHEMBL6018680

CCCCC(CC)COC([O])CC(CC)CCC

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 4/20 0.45
TDP1 Q9NUW8 3/20 0.45
ATM Q13315 1/20 0.45
ALDH1A1 P00352 8/20 0.40
CA2 P00918 3/20 0.40
RECQL P46063 1/20 0.38
LMNA P02545 3/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP14 P50281 1/20 0.36
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018584 0.89 CYP3A4 (0.37) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL10621265 0.84 CYP3A4 (0.47) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL9675719 0.80 CYP3A4 (0.34) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL5892149 0.77 CYP3A4 (0.55) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL4396918 0.76 CYP3A4 (0.47) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL4268477 0.76 ALDH1A1 (0.56) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL19123836 0.75 CYP3A4 (0.52) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL8217857 0.74 CYP3A4 (0.55) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL18427318 0.74 CYP3A4 (0.62) CYP3A4L3MBTL1TSHRTDP1ATM
SCHEMBL4654193 0.74 ALDH1A1 (0.54) CYP3A4L3MBTL1TSHRTDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135491-B2 5-Aryltetrazole compounds and uses thereof INOTEK PHARMACEUTICALS CORP. (US) 2006-11-14 US disclosed
US-7087631-B2 Aryltetrazole compounds, and compositions thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2006-08-08 US disclosed
US-20060135519-A2 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF NIVOROZHKIN ALEXANDER 2006-06-22 US disclosed
US-20050159418-A1 5-Aryltetrazoles compounds and compositions thereof NIVOROZHKIN ALEX (US) 2005-07-21 US disclosed
US-20050159467-A1 5-Aryltetrazole compounds and uses thereof NIVOROZHKIN ALEX (US) 2005-07-21 US disclosed
EP-1542980-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR Inotek Pharmaceuticals Corporation (US) 2005-06-22 EP disclosed
US-20040116423-A1 5-Aryltetrazole compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION 2004-06-17 US disclosed
WO-2004009563-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR INOTEK PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135519-A2 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF CASP5, NOX5, IL5 CYP3A4 336/4885L3MBTL1 1235/4885TSHR 2774/4885
US-20050159467-A1 5-Aryltetrazole compounds and uses thereof NLRP3, XDH, CASP5 CYP3A4 325/4885L3MBTL1 723/4885TSHR 2226/4885
US-20050159418-A1 5-Aryltetrazoles compounds and compositions thereof NLRP3, CASP5, CASP3 CYP3A4 338/4885L3MBTL1 889/4885TSHR 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.